Collegium Pharmaceutical Inc (COLL) Hedge Fund & Institutional Holdings (Q2 2026)

COLL ranks #2266 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

280 institutions disclose a position in COLL, but none treat it as a major bet — even Ballast Asset Management, LP, its most concentrated holder, allocates just 1.6% of its own portfolio to it.

Israel Englander has added to its COLL position for two straight quarters, increasing it by $23.4M to reach $26.7M today.

Emerald Advisers, LLC has trimmed its COLL position for two straight quarters, cutting it by $29.1M while still holding $38.0K.

COLL is up 1.3% today, and institutions have been net buyers of $138.7M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

COLL posted net income of $47.9M over the trailing twelve months, and currently trades at a P/E of 20.1.

• Profitable — net income of $47.9M over the trailing twelve months
• Revenue grew 14.3% year over year
• Net income improved year over year, from $36.3M to $47.9M
• Generated $329.3M in positive operating cash flow
• Current ratio of 1.57x — enough short-term assets to cover short-term liabilities
• Liabilities run 4.49x equity — a highly leveraged balance sheet worth noting